Novartis's Afinitor gets EU approval for kidney cancer
This article was originally published in Scrip
Executive Summary
Novartis's mTOR inhibitor Afinitor (everolimus) has received EU approval for the treatment of advanced renal cell carcinoma patients whose disease progressed on or after treatment with the VEGF pathway inhibitors approved for the disease.